Common Shares are Expected to Begin Trading
Tomorrow on December 9, 2021, Under
Ticker "VLNS"
KELOWNA, BC, Dec. 8, 2021 /CNW/ - The Valens Company
Inc. (TSX: VLNS) (Nasdaq: VLNS) (the "Company" "The Valens
Company" or "Valens"), a leading manufacturer of cannabis products,
announces that the Company's application to list its common shares
on Nasdaq Capital Market ("Nasdaq") has been approved. The
Company's common shares (the "Common Shares") are expected to
commence trading on Nasdaq under the symbol "VLNS" on December 9, 2021.
Valens' common shares will continue to be listed and trade on
the Toronto Stock Exchange (TSX) under the symbol "VLNS". The
Company's shares will continue to trade on the OTCQX under the
symbol "VLNCD" until trading on Nasdaq commences. Shareholders are
not required to take any action as a result of the up-listing and
symbol change.
Tyler Robson, Chief Executive
Officer and Chair of The Valens Company said, "Our Nasdaq listing
represents yet another important milestone that reflects our
commitment to all of our shareholders as we continue to advance our
global growth initiatives by capitalizing on the legalization of
cannabis around the world and strengthening our corporate
governance. I'm exceptionally proud of our team and the platform we
have built here in Canada. Looking
forward, we will continue to build a company focused on product
innovation and advancing our intellectual property to create
products that consumers enjoy. Listing on Nasdaq is the next step
to our capital markets strategy. We believe this listing will
enable Valens and its shareholders greater access to liquidity,
increased corporate visibility, and a broader shareholder base, in
an effort to create long-term shareholder value."
The Company's listing on Nasdaq remains subject to satisfaction
of all applicable listing and regulatory requirements. In
conjunction with this Nasdaq listing, Valens' common shares will
become DWAC/FAST eligible for U.S. shareholders.
At Valens, it's Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis
products with a mission to bring the benefits of cannabis to the
world. The Company provides proprietary cannabis processing
services, in addition to best-in-class product development,
manufacturing, and commercialization of cannabis consumer packaged
goods. The Valens Company's high-quality products are formulated
for the medical, health and wellness, and recreational consumer
segments, and are offered across all cannabis product categories
with a focus on quality and innovation. The Company also
manufactures, distributes, and sells a wide range of CBD products
in the United States through its
subsidiary Green Roads, and distributes medicinal cannabis products
to Australia through its
subsidiary Valens Australia. In partnership with brand houses,
consumer packaged goods companies and licensed cannabis producers
around the globe, the Company continues to grow its diverse product
portfolio in alignment with evolving cannabis consumer preferences
in key markets. Through Valens Labs,
the Company is setting the standard in cannabis testing and
research and development with Canada's only ISO17025 accredited analytical
services lab, named The Centre of Excellence in Plant-Based Science
by partner and scientific world leader Thermo Fisher Scientific.
Discover more on The Valens Company at
http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All
information included in this press release, including any
information as to the future financial or operating performance and
other statements of The Valens Company that express management's
expectations or estimates of future performance, other than
statements of historical fact, constitute forward-looking
information or forward-looking statements within the meaning of
applicable securities laws and are based on expectations, estimates
and projections as of the date hereof. Forward-looking statements
are included for the purpose of providing information about
management's current expectations and plans relating to the future.
Wherever possible, words such as "plans", "expects", "scheduled",
"trends", "forecasts", "future", "indications", "potential",
"estimates", "predicts", "anticipate", "to establish", "believe",
"intend", "ability to", or statements that certain actions, events
or results "may", "should", "could", "would", "might", "will", or
are "likely" to be taken, occur or be achieved, or the negative of
these words or other variations thereof, have been used to identify
such forward-looking information. Specific forward-looking
statements include, without limitation, all disclosure regarding
future results of operations, future outcomes of transactions,
economic conditions, and anticipated courses of action. Investors
and other parties are advised that there is not necessarily any
correlation between the number of SKUs manufactured and shipped and
revenue and profit, and undue reliance should not be placed on such
information.
The risks and uncertainties that may affect forward-looking
statements include, among others, Canadian regulatory risk,
Australian regulatory risk, U.S. regulatory risk, U.S. border
crossing and travel bans, the uncertainties, effects of and
responses to the COVID-19 pandemic, reliance on licenses, expansion
of facilities, competition, dependence on supply of cannabis and
reliance on other key inputs, dependence on senior management and
key personnel, general business risk and liability, regulation of
the cannabis industry, change in laws, regulations and guidelines,
compliance with laws, limited operating history, vulnerability to
rising energy costs, unfavourable publicity or consumer perception,
product liability, risks related to intellectual property, product
recalls, difficulties with forecasts, management of growth and
litigation, many of which are beyond the control of The Valens
Company. For a more comprehensive discussion of the risks faced by
The Valens Company, and which may cause the actual financial
results, performance or achievements of The Valens Company to be
materially different from estimated future results, performance or
achievements expressed or implied by forward-looking information or
forward-looking statements, please refer to The Valens Company's
latest Annual Information Form filed with Canadian securities
regulatory authorities at www.sedar.com or on The Valens Company's
website at www.thevalenscompany.com. The risks described in such
Annual Information Form are hereby incorporated by reference
herein. Although the forward-looking statements contained herein
reflect management's current beliefs and reasonable assumptions
based upon information available to management as of the date
hereof, The Valens Company cannot be certain that actual results
will be consistent with such forward-looking information. The
Valens Company cautions you not to place undue reliance upon any
such forward-looking statements. The Valens Company disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by applicable law. Nothing herein
should be construed as either an offer to sell or a solicitation to
buy or sell securities of The Valens Company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-valens-company-to-begin-trading-on-nasdaq-capital-market-301440651.html
SOURCE The Valens Company Inc.